Body Composition Parameters May Be Prognostic Factors in Upper Urinary Tract Urothelial Carcinoma Treated by Radical Nephroureterectomy

Yulong Pan1,2, Zeyu Chen1†, Lanqing Yang1†, Xingyuan Wang1, Zeng Yi1, Liang Zhou2, Yongjiang Chen2, Lu Yang1, Hui Zhuo2, Yige Bao1* and Qiang Wei1*

1 West China Hospital, Sichuan University, Chengdu, China, 2 Department of Urology, Chengdu Third People’s Hospital, Chengdu, China

Objective: This study assessed the association between body composition and prognosis of patients with upper urinary tract urothelial carcinoma (UTUC) patients treated by radical nephroureterectomy.

Methods: We retrospectively collected baseline data on age, sex, body mass index (BMI), hypertension, diabetes, and tumor-related factors. Computed tomography (CT) scans were performed to measure body composition parameters such as muscle attenuation (MA), total abdominal muscle area (TAMA), visceral fat area (VFA), intermuscular fat area (IMF), and lateral/posterior perirenal fat thickness (L/P PNF), visceral fat density (VD), and subcutaneous fat density (SD). Patient follow-up was conducted via telephone or in the clinic. The endpoints of follow-up were all-cause death, local progression or distant metastasis. Survival analysis was analyzed using the Kaplan-Meier method, and risk factors associated with prognosis were identified using univariate and multivariate Cox proportional hazard analyses.

Results: Among the 273 UTUC patients (median age, 68 years) enrolled in our study, 102 had a BMI > 24.0, 100 suffered from diabetes, and 120 had hypertension. A large proportion of patients (189) had high grade tumors. Across all patients, 1- and 3-year rates for overall survival were 86.45% and 75.55%; local progression-free survival, 92.11% and 89.67%; and distant metastasis-free survival, 85.23% and 80.17%. Based on the Cox regression analysis, MA, TAMA, and SMI significantly reduced the risk of local progression (p < 0.05), while PPNF = 1 point reduced the risk of distant metastasis (p < 0.05). Overall survival was significantly associated with MA, TAMA, and SMI (p < 0.05).
60% of UTUCs are invasive at diagnosis (1). The standard of all renal tumors and 5-10% of all urothelial carcinomas; about urothelial carcinoma (UTUC) accounts for approximately 10% as well as various tumor characteristics (stage, primary site, parameters (see below), diagnosis of hypertension and diabetes, including age, sex, weight, height, BMI, body composition tissue, which stores fat. BMI is a relatively crude measure that does not take into account the individual effects of lean tissue, bones, and adipose tissue, nor does it describe the distribution of fat in the body (5–7). Studies have reported differences in BMI based on ethnicity (8), which therefore has confounded efforts to examine the association between BMI and prognosis. Additionally, muscles and adipose tissue are increasingly being recognized as separate organs, since they play important, but unique roles in the occurrence, progression, prognosis, and other aspects of diseases (5–7).

Apart from its effect on disease prognosis, body composition is also associated with risk of surgical complications, therapeutic efficacy, and treatment-related side effects (9). In this study, we retrospectively analyzed whether individual body composition parameters, including muscle and adipose tissue, are associated with prognosis of UTUC patients treated by RNU.

**INTRODUCTION**

Urothelial cancer is an aggressive disease associated with high recurrence and progression rates (1). Upper urinary tract urothelial carcinoma (UTUC) accounts for approximately 10% of all renal tumors and 5-10% of all urothelial carcinomas; about 60% of UTUCs are invasive at diagnosis (1). The standard treatment for UTUC is radical nephroureterectomy (RNU) along with excision of the bladder cuff (1).

Body mass index (BMI) is an international indicator of body weight and thinness, as well as of an individual’s health status. Studies have reported a strong correlation between BMI and prognosis in tumor patients (2, 3). However, individuals with the same BMI can have distinct body compositions, due to differences in body structure and functioning (4). The human body consists of lean tissue (i.e. muscle tissue), and adipose tissue, which stores fat. BMI is a relatively crude measure that does not take into account the individual effects of lean tissue, bones, and adipose tissue, nor does it describe the distribution of fat in the body (5–7). Studies have reported differences in BMI based on ethnicity (8), which therefore has confounded efforts to examine the association between BMI and prognosis. Additionally, muscles and adipose tissue are increasingly being recognized as separate organs, since they play important, but unique roles in the occurrence, progression, prognosis, and other aspects of diseases (5–7).

Apart from its effect on disease prognosis, body composition is also associated with risk of surgical complications, therapeutic efficacy, and treatment-related side effects (9). In this study, we retrospectively analyzed whether individual body composition parameters, including muscle and adipose tissue, are associated with prognosis of UTUC patients treated by RNU.

**MATERIALS AND METHODS**

**Study Population**

We retrospectively collected relevant data on UTUC patients registered in our hospital information system between January 2014 and June 2017. We included patients who received a pathological diagnosis of UTUC and had undergone RNU treatment at our hospital. We excluded patients who showed signs of other malignant neoplasms and those with metastatic tumors at local lymph nodes or distant organs at initial diagnosis. We collected data on baseline and clinical characteristics, including age, sex, weight, height, BMI, body composition parameters (see below), diagnosis of hypertension and diabetes, as well as various tumor characteristics (stage, primary site, laterality, grade, and maximum diameter). Due to the retrospective nature of this study, no information on alcohol intake, diet and exercises could be obtained, except for smoking.

This study was approved by the Ethics Committee of our hospital.

**Computed Tomography Scans and Body Composition Measurements**

For each patient, results of computed tomography (CT) scan using a 64-slice multi detector CT scanner (Somatom Definition Flash, Siemens AG, Erlangen, Germany) was obtained from the database of our center, and conducted segmentation of the CT data using Volume. We followed previously described methods to measure body composition parameters.

We measured total abdominal muscle area (TAMA), which includes the rectus abdominis, intra-abdominal oblique, external oblique, transverse abdominis, paraspinal, and psoas muscles. We also measured total psoas muscle area (TPA), visceral fat area (VFA), subcutaneous fat area (SFA), visceral fat density (VD) and subcutaneous fat density (SD). Mean muscle attenuation (MA) and intermuscular fat tissue were measured at the level of the L3 inferior endplate, while the axial/transversal psoas thickness (APT/TPT) and subcutaneous fat thickness (SCF) were measured at the level of the umbilicus. Perirenal fat area (PFA) and lateral/posterior perirenal fat thickness (L/P PN F) were measured at the level of the renal vein (< 1 cm = 0 points, 1.1–1.9 cm = 1 point, > 2 cm = 2 points) (10). Tissue was defined as fat if its CT value fell within a range from -150 to -50 Hounsfield units, or as muscle if its CT value fell within a range from -29 to 150 Hounsfield units (10, 11).

**Data Standardization and End Points of Study**

Using data collected on fat and muscle area, we derived height-normalized indices (reported as cm²/m²) for subcutaneous fat (SFI), intermuscular fat (IFI), visceral fat (VFI), skeletal muscle (SMI), and psoas muscle (PMI) using data collected on fat and muscle area. Similarly, psoas muscle thickness, expressed as standardized APT and TPT, was normalized to height and reported as mm/m.

Based on previous literature, we calculated a VFA to SFA ratio (V/S) to provide a single measure of abdominal fat: an elevated V/S indicated higher visceral fat than subcutaneous fat content, and a V/S ≥ 0.4 was used to define visceral obesity (12). The endpoints of our study were overall survival (OS), defined as all-cause death; local progression (local metastasis or recurrence); and distant metastasis.
Patients Follow up
Follow-up was conducted based on the risk stratification of patients using EAU guidelines (1). Cystoscopy was conducted for low-risk patients at three months after RNU. If no recurrence was found in the bladder, subsequent cystoscopy was performed every three months for the first two years, then every six months thereafter until five years, when checkups were done annually. In the case of high-risk patients, CT urograms and chest CTs were performed every six months for two years, then annually.

Statistical Analyses
All statistical analyses were performed using Empower 2.0. Differences in baseline characteristics were assessed using a chi-squared test. Continuous data were presented as median (min-max) and categorical data as frequency (%). Patient survival was analyzed using the Kaplan-Meier method. Further, a univariate Cox proportional hazard model was used to analyze OS, local progression-free survival (LPFS), and distant metastasis-free survival (DMFS). After adjusting for tumor stage, grade, tumor size (maximum diameter cut off at 3cm) and lymph node invasion, we included all significant variables (p < 0.05) in a multi-variate Cox proportional hazard analysis.

RESULTS
Baseline Characteristics
Among the 273 UTUC patients enrolled in this study, who were aged 30 to 92 years (median 68), 102 patients were considered as overweight (BMI > 24). Many of these patients also suffered from diabetes (n = 100) and hypertension (n = 120). A large proportion of these patients had tumors diagnosed as high-grade based on pathology (n = 189), including 90 patients with T3 tumors and 27 with T4 tumors. Further details on baseline characteristics are provided in Table 1.

Patient Survival
During follow-up, we found that 24 (9.56%) patients experienced local progression after RNU, 48 (19.13%) suffered distant metastasis, and 59 (23.51%) died. Kaplan-Meier analysis indicated OS rates of 86.45% at 1 year and 75.55% at 3 years (Figure 1A). The corresponding LPFS rates 92.11% and 89.67% (Figure 1B), while DMFS rates were 85.23% and 80.17% (Figure 1C).

Prognostic Factors
The uni-variate Cox proportional hazard analyses showed that higher values of MA, TAMA, TPT, SMI, and standardized TPT were associated with lower OS in patients (p < 0.1; Table 2). An increase in PMI, MA, TAMA, TPA, TPT, or APT was associated with lower incidence of local progression, while MA, TPA, PPNF =1 point, PMI, and standardized TPT was negatively associated with risk of distant metastasis.

TABLE 1 | Baseline characteristics of study cohort.

| Parameter | Median (Min-Max) |
|-----------|------------------|
| Age       | 68.00 (30.00-92.00) |
| Muscle attenuation (MA) | 30.70 (1.20-57.10) |
| IMFI (intermuscular) | 5.14 (0.62-17.65) |
| TAMA      | 53.87 (12.81-104.12) |
| TPA       | 8.50 (2.18-42.44) |
| VFA       | 58.48 (6.52-155.53) |
| SFA       | 55.09 (6.27-199.02) |
| Abdominal wall fat thickness | 1.83 (0.31-4.43) |
| TPT       | 2.87 (1.45-5.56) |
| APT       | 3.90 (1.94-5.43) |
| LPNF      | 1.68 (0.10-5.05) |
| PPNF      | 1.17 (0.10-4.43) |
| PFA       | 7.51 (0.21-29.30) |
| SMIF       | 20.63 (5.69-38.24) |
| PMI       | 3.24 (0.92-13.86) |
| SFA (standardized) | 21.09 (2.30-70.51) |
| TPT (standardized) | 2.39 (0.79-2570.18) |
| APT (standardized) | 2.41 (1.21-3.28) |
| VFA/SFA   | 1.05 (0.22-2.89) |
| VFA (standardized) | 22.84 (2.49-40.00) |
| (VFA+SFA+IFA)/TAMA | 2.46 (0.24-3.64) |
| (VD (visceral fat density)) | -96.30 (-116.10-74.30) |
| SD (subcutaneous fat density) | -102.60 (-124.40-74.30) |

| Parameter | Median (Min-Max) |
|-----------|------------------|
| Gender | Male 148 (54.21%) |
| BMI | Female 125 (45.79%) |
| <18.5 | 29 (10.78%) |
| 18.5-23.9 | 138 (51.30%) |
| 24.0-26.9 | 64 (23.79%) |
| 27.0-29.9 | 35 (13.01%) |
| ≥29.9 | 3 (1.12%) |
| IFG (≥ 5.6) or type 2 diabetes mellitus | Yes 169 (62.83%) |
| Hypertension (≥ 130/85mmHg) | No 100 (37.17%) |
| Hydronephrosis | Yes 153 (56.04%) |
| Primary site | No 120 (43.96%) |
| Renal pelvis | Yes 156 (58.65%) |
| Ureter | Male 148 (54.21%) |
| T stage | Female 125 (45.79%) |
| T1 | 8 (2.96%) |
| T2 | 95 (35.19%) |
| T3 | 50 (18.52%) |
| T4 | 90 (33.33%) |
| T stage | Yes 156 (58.65%) |
| Grade | No 110 (41.35%) |
| Low | Yes 156 (58.65%) |
| High | Male 148 (54.21%) |
| Tumor size (maximum diameter) | Female 125 (45.79%) |
| <3cm | 82 (30.37%) |
| ≥3cm | 188 (69.63%) |
| Lymph-node invasion | Without 252 (93.68%) |
| Identified | Yes 53 (22.94%) |

(Continued)
After adjusting for confounding factors, the results of the adjusted model analysis showed that there was a significant association between MA, TAMA, SMI and OS (P<0.05). Additionally, MA, IMF, TAMA, TPA, TPT, APT, SMI and PMI were found to be inversely related to the risk of local progression, while PPNF = 1 point was associated with significantly lower risk of distant metastasis (Table 3).

**DISCUSSION**

Although both UTUC and bladder cancer involve malignant tumors in the urinary epithelium, UTUC has typically invaded the muscle layer by the time it is diagnosed. Therefore, UTUC patients have a significantly worse prognosis than those with bladder cancer, and they remain at high risk of tumor recurrence and metastasis even after RNU (1). Few studies have examined the combined prognostic effect of muscle and fat tissues, particularly in the Chinese population. To our knowledge, this is the first study examining the relationship of muscle and fat-related parameters with survival outcomes in UTUC patients treated with RNU. We found that muscle quality, muscle quantity, and perirenal fat thickness correlated significantly with survival of UTUC patients after RNU.

Studies involving UTUC patients have typically focused on various factors affecting disease prognosis, including tumor-related factors such as pathology stage and grade, or clinical factors such as physical status and smoking history (1). Age, tumor grade, location, T stage, growth pattern, lymphovascular invasion, and histological variation can affect the prognosis of UTUC patients treated with RNU (1). However, these factors depend on postoperative pathological examinations. Few large studies have examined preoperative factors that may help predict prognosis of UTUC patients.

Fat and muscle are two important components of the body that play distinct, yet significant roles in the management of diseases (2, 6). Clinical imaging has proved to be reliable for the assessment of the quantity and distribution of muscle and fat in the body (13, 14). The analysis of CT scans at the level of the third lumbar spine vertebra is considered the gold standard for measuring body composition parameters in muscle and adipose tissue. Among cancer patients undergoing chemotherapy, molecular-targeted therapy or immunotherapy (3, 9, 15), the loss of muscle mass or quality has been associated with decreased OS, increased incidence of surgical complications, as well as increased frequency and severity of adverse reactions. The prognostic effects of adipose tissue parameters vary based on the tumor type (2, 6).

Body composition parameters associated with skeletal mass (SMI and MA) have been identified as prognostic factors in lung cancer, esophageal cancer, gastric cancer, and pancreatic cancer (3, 9, 15, 16). MA is used to measure muscle quality, while SMI is used to measure body muscle mass (17, 18). However, it is unclear whether muscle mass (SMI) or quality (MA) is more suitable to understand disease prognosis in tumor patients (18). For example, in patients with non-small cell lung cancer and pancreatic cancer, only MA is a prognostic factor for OS. Low MA is associated with obesity, diabetes, loss of exercise and muscle atrophy. Studies have found that the attenuation density of skeletal muscle positively correlates with muscle quality and strength, and negatively correlates with muscle fiber fat content. Indeed, attenuation density of skeletal muscle varies inversely with the lipid drop content in muscle fibers (19). The mechanisms underlying these changes in muscle appear to affect its quality earlier, or more severely, than its quantity.

Based on the observed effects of muscle mass and quantity on prognosis, preoperative targeted intervention of muscle state may be an effective way to improve outcomes. Our results argue for preoperative efforts to improve muscle mass of

![FIGURE 1](A) Overall survival of all patients; (B) Local progression free survival of all patients; (C) Distant metastasis free survival of all patients.
UTUC patients. Studies have reported that resistance training alone does not significantly improve muscle mass (17). Further studies are necessary to identify approaches, perhaps combining exercise, nutrition, and drugs, that can effectively build muscle mass in UTUC patients.

Based on previous studies, we analyzed the prognostic effects of psoas muscle parameters (PMI and standardized TPT) on UTUC patients treated with RNU (20, 21). Patients with higher MA, TAMA and SMI values tended to be at lower risk of all-cause death. MA, IMF, TAMA, TPA, TPT, APT, SMI and PMI were associated with a reduction in local progression of the tumor; PPNF = 1 point was also associated with a reduced risk of distant metastasis. Our findings support the idea that psoas characteristics serve as markers of sarcopenia (20, 21).

Studies have reported that fat parameters (VFA, SFA, SCF, IFA, SD, VD) measured at the third lumbar vertebra were associated with prognosis of patients with adenoma-derived tumors, including renal cancer, colorectal cancer, or gastric carcinoma (11, 22). We found that these parameters had no effect on the prognosis of UTUC patients. This can be due to the small sample size in our study, or the differences between urothelial carcinoma and adenocarcinoma at the cellular level:

**TABLE 3 | Multivariate cox proportional hazard analysis for risk factors of patients’ prognosis.**

|   | OS | LPS | DM |
|---|----|----|----|
|   | HR (95%CI) p-value | HR (95%CI) p-value | HR (95%CI) p-value |
| **MA** | 0.96 (0.93, 0.98) 0.0015 | 0.96 (0.92, 1.00) 0.0587 | 0.96 (0.93, 0.99) 0.0051 |
| **IMF** | 1.05 (0.96, 1.14) 0.2946 | 0.88 (0.73, 1.06) 0.1638 | 1.02 (0.93, 1.12) 0.6966 |
| **TAMA** | 0.98 (0.97, 1.00) 0.0556 | 0.97 (0.95, 1.00) 0.0718 | 0.99 (0.97, 1.01) 0.2523 |
| **TPA** | 0.96 (0.90, 1.02) 0.1815 | 0.81 (0.69, 0.96) 0.0161 | 0.92 (0.84, 1.00) 0.0454 |
| **VFA** | 1.00 (0.99, 1.01) 0.7856 | 0.99 (0.98, 1.01) 0.3959 | 1.00 (0.99, 1.01) 0.6543 |
| **SFA** | 1.00 (0.99, 1.01) 0.5291 | 1.00 (0.98, 1.01) 0.5658 | 1.00 (0.99, 1.01) 0.7772 |
| Abdominal wall fat thickness | 1.23 (0.85, 1.78) 0.2781 | 1.31 (0.69, 2.49) 0.4015 | 1.03 (0.68, 1.57) 0.8775 |
| **TPT** | 0.62 (0.40, 0.96) 0.0339 | 0.36 (0.16, 0.83) 0.0162 | 0.84 (0.54, 1.32) 0.4491 |
| **APT** | 0.94 (0.61, 1.46) 0.7910 | 0.50 (0.24, 1.03) 0.0593 | 0.96 (0.60, 1.53) 0.8704 |
| **LPNF** | 0.94 (0.66, 1.33) 0.7189 | 0.78 (0.41, 1.49) 0.4598 | 0.99 (0.69, 1.42) 0.9478 |
| **PPNF** | 1.04 (0.69, 1.56) 0.8514 | 0.82 (0.38, 1.74) 0.5971 | 1.10 (0.72, 1.68) 0.6518 |
| **PFA** | 0.98 (0.92, 1.04) 0.4224 | 0.95 (0.86, 1.06) 0.3808 | 0.99 (0.93, 1.05) 0.7929 |
| **PMI** | 0.93 (0.87, 0.98) 0.0143 | 0.90 (0.83, 0.99) 0.0252 | 0.95 (0.88, 1.01) 0.0798 |
| **SFA(standardized)** | 1.00 (0.98, 1.02) 0.0053 | 1.00 (0.98, 1.02) 0.0053 | 0.99 (0.94, 1.05) 0.6732 |
| **TPT(standardized)** | 0.72 (0.48, 1.05) 0.0765 | 0.56 (0.35, 0.89) 0.0169 | 0.78 (0.62, 1.00) 0.0507 |
| **VFA/SFA** | 0.98 (0.53, 1.81) 0.9443 | 0.99 (0.96, 1.04) 0.7999 | 1.00 (0.98, 1.03) 0.6957 |
| **VFA/SFA=IFA** | 1.15 (0.51, 2.57) 0.7417 | 0.56 (0.17, 1.80) 0.3275 | 0.55 (0.28, 1.08) 0.0810 |
| **VFA/SFA=IFA** | 0.96 (0.91, 1.01) 0.0932 | 0.57 (0.36, 0.96) 0.1697 | 0.79 (0.62, 1.00) 0.0363 |
| **VFA/SFA=IFA** | 1.00 (0.97, 1.02) 0.07228 | 0.99 (0.86, 1.02) 0.01178 | 0.97 (0.92, 1.03) 0.03063 |
| **VFA/SFA=IFA** | 1.11 (0.88, 1.39) 0.3895 | 1.13 (0.76, 1.66) 0.5503 | 1.15 (0.90, 1.47) 0.2521 |
| **VFA/SFA=IFA** | 1.02 (0.99, 1.03) 0.02256 | 1.03 (0.98, 1.09) 0.2880 | 1.00 (0.96, 1.04) 0.9938 |
| **VFA/SFA=IFA** | 1.00 (0.97, 1.03) 0.0808 | 1.02 (0.97, 1.07) 0.3878 | 0.99 (0.96, 1.03) 0.6732 |

Pan et al. Body Composition Parameters in UTUC Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6791585
adenocarcinoma cells contain large amounts of lipid droplets, while urothelial carcinoma cells do not, and so lipid metabolism may not play a significant role in the latter cancer. Meanwhile, our results also suggest that perirenal or periureteral adipose tissue may significantly influence urothelial carcinoma invasion and progression.

Our results must be interpreted with caution in the light of certain limitations. The retrospective design of the study and the relatively small cohort are potential sources of bias. It was impossible to retrospectively obtain data on important diagnostic factors associated with sarcopenia, such as grip strength, walking speed, and patient self-report of the SARC-F questionnaire (23). Additionally, we did not have sufficient imaging data to compare changes in body composition before and after RNU treatment. Future work should focus on validating and extending these results.

CONCLUSION

Our findings show that preoperative assessment of body condition that is more finely grained than BMI can help predict prognosis of UTUC patients after RNU. We found that body composition parameters associated with muscle quality and muscle mass, can independently predict prognosis in such patients. Our results may help improve risk stratification of patients and their postoperative management.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Roupret M, Bahjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. *Eur Urol* (2018) 73(1):111–22. doi: 10.1016/j.eururo.2017.07.036

2. Caan BJ, Cespedes Feliciano EM, Koenke CH. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. *Cancer Res* (2018) 78(8):1906–12. doi: 10.1158/0008-5472.CAN-17-3287

3. Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, et al. Prognostic Role of Body Composition Parameters in Gastric/ Gastroesophageal Junction Cancer Patients From the EXPAND Trial. *J Cachexia Sarcopenia Muscle* (2020) 11(1):135–44. doi: 10.1002/jsm.12484

4. Prado CM, Gonzalez MC, Heymsfield SB. Body Composition Phenotypes and Obesity Paradox. *Curr Opin Clin Nutr Metab Care* (2015) 18(6):535–51. doi: 10.1097/MCO.0000000000000216

5. Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI Paradox to the Obesity Paradox: The Obesity-Mortality Association in Coronary Heart Disease. *Obes Rev* (2016) 17(10):989–1000. doi: 10.1111/ obr.12440

6. Brown JC, Cespedes Feliciano EM, Caan BJ. The Evolution of Body Composition in Oncology-Epidemiology, Clinical Trials, and the Future of Patient Care: Facts and Numbers. *J Cachexia Sarcopenia Muscle* (2018) 9(7):1200–8. doi: 10.1002/jsm.12379

7. Goossens GH. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. *Obes Facts* (2017) 10(3):207–15. doi: 10.1159/000471488

8. Kokkinos P, Myers J, Faselis C, Doumas M, Kheirbek R, Nylen E. BMI-Mortality Paradox and Fitness in African American and Caucasian Men With Type 2 Diabetes. *Diabetes Care* (2012) 35(5):1021–7. doi: 10.2337/dc11-2407

9. Linder N, Schaudinn A, Langenhan K, Krenzien F, Hau HM, Benzing C, et al. Power of Computed-Tomography-Defined Sarcopenia for Prediction of Morbidity After Pancreactoduodenectomy. *BMC Med Imaging* (2019) 19(1):32. doi: 10.1186/s12880-019-0332-6

10. Kawamura N, Saito K, Inoue M, Ito M, Kijima T, Yoshida S, et al. Adherent Perinephric Fat in Asian Patients: Predictors and Impact on Perioperative Outcomes of Partial Nephrectomy. *Urol Int* (2018) 101(4):437–42. doi: 10.1159/000494068

11. Gill TS, Varghese BA, Hwang DH, Cen SY, Aron M, Aron M, et al. Juxtaumbural Perinephric Fat Analysis in Clear Cell Renal Cell Carcinoma. *Abdom Radiol (NY)* (2019) 44(4):1470–80. doi: 10.1007/s00261-018-1848-x

12. Clark W, Siegel EM, Chen YA, Zhao X, Parsons CM, Hernandez JM, et al. Quantitative Measures of Visceral Adiposity and Body Mass Index in Predicting Rectal Cancer Outcomes After Neoadjuvant Chemoradiation. *J Am Coll Surg* (2013) 216(6):1070–81. doi: 10.1016/j.jamcollsurg.2013.01.007

13. Henry Kvist BC, Ulla G, Ulf T, Lars S. Total and Visceral Adipose-Tissue Volumes Derived From Measurements With Computed Tomography in Adult Men and Women Predictive Equations. *Am J Clin Nutr* (1988) 48:11. doi: 10.1093/ajcn/48.6.1351

14. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A Practical and Precise Approach to Quantiﬁcation of Body Composition in Cancer Patients Using Computed Tomography Images Acquired During Routine Care. *Appl Physiol Nutr Metab* (2008) 33(5):997–1006. doi: 10.1113/H08-075

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee on Biomedical Research, West China Hospital of Sichuan University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YP: data acquisition, investigation, writing - original draft, and formal analysis. ZC: conceptualization, data curation, formal analysis, software, validation, and writing - review & editing. LaY: software, visualization, and data acquisition. XW: data curation and software. ZY: formal analysis and investigation. LZ: visualization and data acquisition. YC: Writing - review & editing. LuY: software, investigation, and supervision. HZ: investigation and methodology. YB: supervision, validation, and project administration. QW: supervision, project administration, funding acquisition. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant number: 81500522) and Science & Technology Department of Sichuan Province (Grant number: 2020YFS0090, 2020YFS0046).
15. Huang X, Ma J, Li L, Zhu XD. Severe Muscle Loss During Radical Chemoradiotherapy for Non-Metastatic Nasopharyngeal Carcinoma Predicts Poor Survival. *Cancer Med* (2019) 8(15):6604–13. doi: 10.1002/cam4.2538

16. Cespedes EM, Feliciano WYC, Bradshaw PT, Prado CM, Alexeeff S, Albers KB, et al. Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors. *J Clin Oncol* (2019) 37(28):9. doi: 10.1200/JCO.19.00286

17. Goodpaster CLC BH, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E, et al. Attenuation of Skeletal Muscle and Strength in the Elderly The Health ABC Study. *J Appl Physiol* (2001) 90:9. doi: 10.1152/jappl.2001.90.6.2157

18. Heymsfield SB, Gonzalez MC, Lu J, Jia G, Zheng J. Skeletal Muscle Mass and Quality: Evolution of Modern Measurement Concepts in the Context of Sarcopenia. *Proc Nutr Soc* (2015) 74(4):355–66. doi: 10.1017/S0029665115000129

19. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and Clinical Implications of Sarcopenic Obesity in Patients With Solid Tumours of the Respiratory and Gastrointestinal Tracts: A Population-Based Study. *Lancet Oncol* (2008) 9(7):629–35. doi: 10.1016/S1470-2045(08)70153-0

20. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic Significance of Sarcopenia in Upper Tract Urothelial Carcinoma Patients Treated With Radical Nephroureterectomy. *Cancer Med* (2016) 5(9):2213–20. doi: 10.1002/cam4.795

21. Tsutsumi S, Kawahara T, Teranishi JI, Yao M, Uemura H. A Low Psoas Muscle Volume Predicts Longer Hospitalization and Cancer Recurrence in Upper Urinary Tract Urothelial Carcinoma. *Mol Clin Oncol* (2018) 8(2):320–2. doi: 10.3892/mco.2017.1537

22. Kapoor ND, Twining PK, Groot OQ, Pielkenrood BJ, Bongers MER, Newman ET, et al. Adipose Tissue Density on CT as a Prognostic Factor in Patients With Cancer: A Systematic Review. *Acta Oncol* (2020) 59(12):1–8. doi: 10.1080/0284186X.2020.1800087

23. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. *Age Ageing* (2019) 48(1):16–31. doi: 10.1093/ageing/afz046

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Pan, Chen, Yang, Wang, Yi, Zhou, Chen, Yang, Zhuo, Bao and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.